AstraZeneca gets FDA okay for Imfinzi for endometrial cancer

JHVEPhoto AstraZeneca ( NASDAQ: AZN ) said the FDA has approved its drug Imfinzi, also known as durvalumab, for the treatment of a certain type of endometrial cancer. The FDA approved Imfinzi in combination with carboplatin and paclitaxel followed by Imfinzi as a monotherapy in the treatment of adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, or dMMR. Imfinzi is already approved for the treatment of cancers of the lung, liver and bile ducts.

More on AstraZeneca AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca's Farxiga approved for type 2 diabetes for children as young as 10 AstraZeneca’s Tagrisso gets FDA priority review in lung cancer subtype.